{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-146014","form_type":"8-K","ticker":null,"cik":"0001785345","company_name":"Landos Biopharma, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.098927+00:00","generated_at":"2026-06-01T09:17:52.943998+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie completes acquisition of Landos Biopharma for $20.42/share plus CVR up to $11.14","bullets":["Aggregate closing cash consideration ~$137.5M; Landos shareholders receive $20.42 per share in cash plus one CVR per share.","CVR entitles holders to up to $11.14 in cash upon initiation of first Phase 3 trial of NX-13 for ulcerative colitis by March 31, 2029.","Landos' lead asset NX-13 is a first-in-class oral NLRX1 agonist in Phase 2 for moderate to severe UC (NEXUS study).","Landos' directors resigned and CEO/executive officers left; company becomes wholly owned subsidiary of AbbVie.","Landos common stock to be delisted from Nasdaq before market open on May 24, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-146014","json":"https://secwatch.observer/filing/0001193125-24-146014.json","markdown":"https://secwatch.observer/filing/0001193125-24-146014.md","text":"https://secwatch.observer/filing/0001193125-24-146014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785345/000119312524146014/0001193125-24-146014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785345/000119312524146014/d815685d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:17:52.943998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15ca4b11ddeb5779c3f7f78f858f37dbbc355802","claim":"Landos Biopharma, Inc. underwent a change of control involving AbbVie Inc. for $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share (closed 2024-05-23).","evidence_excerpt":"AbbVie has acquired Landos at a price of $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785345/000119312524146014/0001193125-24-146014-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"AbbVie Inc."},{"label":"Consideration","value":"$20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share"},{"label":"Closing","value":"2024-05-23"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}